• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>DOV Pharmaceutical

DOV Pharmaceutical

  1. CLS: Slow Down, Think Before You Trade

    On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine under review while we revisit our assumptions, and because DOV Pharmaceutical DOVP is entitled to a royalty on any indiplon ...

©2017 Morningstar Advisor. All right reserved.